ArticleAmino acids2026
Plasma branched-chain amino acids in chronic kidney disease: associations with atherogenic lipids and mortality.
Article in Amino acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Branched-chain amino acids (BCAAs) are essential nutrients that promote muscle protein anabolism but also associate with cardiometabolic diseases; however, their role in chronic kidney disease (CKD) remains unclear. We investigated plasma BCAA levels and their associations with metabolic parameters and survival in CKD patients. Plasma BCAA levels, along with clinical and laboratory parameters, were measured in 328 patients with CKD stage 5 (median age 54 years, 60% males). BCAA concentrations in 83 community-dwelling controls (median age 51 years, 66% males) served as comparators. Multivariate linear regression analysis was employed to identify predictors of BCAA levels. Competing risk regression analysis was conducted to assess 5-year risk of all-cause and cardiovascular mortality in relation to total and individual BCAAs (valine, isoleucine, and leucine). Plasma BCAA levels were lower compared to controls (P < 0.0001) and positively associated with triglycerides and the atherogenic index of plasma, while inversely associated with high density lipoprotein-cholesterol (HDL-C), Apo-A, and Lp (a). After adjustments for confounders, low vs. high tertile of total BCAAs associated with increased risk of cardiovascular mortality (sub-hazard ratio [sHR] 2.37, 95% confidence interval [CI], 1.08-5.21) and low tertile of valine associated with higher risk of both all-cause mortality (sHR 2.05, 95% CI 1.10-3.79) and cardiovascular mortality (sHR 2.46, 95% CI 1.15-5.26). In CKD, higher levels of BCAAs associated with an atherogenic lipid profile while lower BCAAs levels associated with increased cardiovascular mortality risk, and low valine was associated with higher both all-cause and cardiovascular mortality risk. Monitoring and potentially modulating BCAA levels could have prognostic or therapeutic implications in advanced CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.